Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant
IBER.U
IBER.U was delisted on the 1st of March, 2023.
18 hedge funds and large institutions have $22.5M invested in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.
27% more capital invested
Capital invested by funds: $17.7M → $22.5M (+$4.76M)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$104K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$17.7K |
| 3 |
Jane Street
New York
|
+$5.86K |
| 4 |
CS
Clear Street
New York
|
+$3.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$623K |
| 2 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$147K |
| 3 |
WC
Wealthspring Capital
West Harrison,
New York
|
-$104K |
| 4 |
SIA
Schechter Investment Advisors
Birmingham,
Michigan
|
-$53.4K |
| 5 |
SMA
Sage Mountain Advisors
Atlanta,
Georgia
|
-$21K |
IBER.U Hedge Fund Activity: Q2 2022 in Review
18 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) for Q2 2022, worth a combined $22.5M — up 27% from $17.7M a quarter earlier.
Fund positioning in IBER.U was balanced in Q2 2022: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $104K. The largest seller was Magnetar Financial, cutting an estimated $623K.
- 18 institutional investors held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $22.5M of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant stock for Q2 2022, up 27% quarter-over-quarter.
- 2 funds opened new Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant positions in Q2 2022 and 2 closed out, a net change of 0 holders.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant buyer in Q2 2022 was Susquehanna International Group, an estimated $104K added.
- The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant seller in Q2 2022 was Magnetar Financial, an estimated $623K sold.
Based on aggregated 13F filings for Q2 2022.